PI3-kinase binds to mutant PDGFR receptor

Stable Identifier
R-HSA-9672172
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Gain-of-function mutants of PDGFRA bind to phosphatidylinositol-3' kinase (PI3K) to activate AKT signaling, as assessed by the presence of phosphorylated AKT in Western blot analysis (Heinrich et al, 2003; Ohashi et al, 2004; reviewed in Corless et al, 2011). Interaction of PI3K with mutant PDGFRA receptors is assumed to occur through binding to phosphorylated Y731 and Y742 as is the case for the wild-type receptor, although this hasn't been directly demonstrated (reviewed in Roskoski, 2018).

Literature References
PubMed ID Title Journal Year
29408302 The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders

Roskoski, R

Pharmacol. Res. 2018
22089421 Gastrointestinal stromal tumours: origin and molecular oncology

Corless, CL, Barnett, CM, Heinrich, MC

Nat. Rev. Cancer 2011
15221957 Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha

Ohashi, A, Kinoshita, K, Isozaki, K, Nishida, T, Shinomura, Y, Kitamura, Y, Hirota, S

Int. J. Cancer 2004
12522257 PDGFRA activating mutations in gastrointestinal stromal tumors

Heinrich, MC, Corless, CL, Duensing, A, McGreevey, L, Chen, CJ, Joseph, N, Singer, S, Griffith, DJ, Haley, A, Town, A, Demetri, GD, Fletcher, CD, Fletcher, JA

Science 2003
Participants
Participant Of
Normal reaction
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!